EA202090637A1 - Способы применения дипивефрина - Google Patents

Способы применения дипивефрина

Info

Publication number
EA202090637A1
EA202090637A1 EA202090637A EA202090637A EA202090637A1 EA 202090637 A1 EA202090637 A1 EA 202090637A1 EA 202090637 A EA202090637 A EA 202090637A EA 202090637 A EA202090637 A EA 202090637A EA 202090637 A1 EA202090637 A1 EA 202090637A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dipivephrine
epinephrine
subject
disease
salt
Prior art date
Application number
EA202090637A
Other languages
English (en)
Inventor
Минбао Чжан
Original Assignee
Инсайгнис Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсайгнис Терапьютикс, Инк. filed Critical Инсайгнис Терапьютикс, Инк.
Publication of EA202090637A1 publication Critical patent/EA202090637A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

Настоящее изобретение обеспечивает способ системной доставки терапевтически эффективного количества эпинефрина субъекту, включающий оральное введение дипивефрина или соли дипивефрина субъекту. Изобретение также включает способ лечения заболевания, поддающегося лечению с помощью in vivo системной доставки эпинефрина, включающий введение дипивефрина или соли дипивефрина субъекту, нуждающемуся в in vivo системной доставке эпинефрина. Заболевание может представлять собой респираторное заболевание, анафилаксию, рак или микробную инфекцию. Изобретение также включает орально растворимые таблетки дипивефрина или дипивефрина HCl.
EA202090637A 2017-09-08 2018-09-10 Способы применения дипивефрина EA202090637A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555854P 2017-09-08 2017-09-08
PCT/US2018/050223 WO2019051387A1 (en) 2017-09-08 2018-09-10 METHODS OF USING DIPIVECHINE

Publications (1)

Publication Number Publication Date
EA202090637A1 true EA202090637A1 (ru) 2020-06-29

Family

ID=63686134

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090637A EA202090637A1 (ru) 2017-09-08 2018-09-10 Способы применения дипивефрина

Country Status (14)

Country Link
US (2) US11213496B2 (ru)
EP (1) EP3678648B1 (ru)
JP (2) JP6837700B2 (ru)
KR (1) KR102182559B1 (ru)
CN (1) CN111565716B (ru)
AU (1) AU2018330329B2 (ru)
BR (1) BR112020004586A2 (ru)
CA (1) CA3075271C (ru)
DK (1) DK3678648T3 (ru)
EA (1) EA202090637A1 (ru)
ES (1) ES2954361T3 (ru)
IL (1) IL272851B (ru)
SG (1) SG11202001397VA (ru)
WO (1) WO2019051387A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3678648T3 (da) 2017-09-08 2023-09-11 Insignis Therapeutics Inc Fremgangsmåder til anvendelse af dipivefrin
EP3930685A1 (en) 2019-03-01 2022-01-05 Insignis Therapeutics, Inc. Dipivefrin orally disintegrating tablet formulations
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
WO2023076477A2 (en) * 2021-10-27 2023-05-04 Insignis Therapeutics, Inc. Orally disintegrating tablet for epinephrine prodrug formulations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904671A (en) * 1969-04-01 1975-09-09 Sterling Drug Inc Esters of 3-(hydroxy or hydroxymethyl)-4-hydroxyphenyl aminomethyl ketones
NL7213759A (ru) * 1971-10-19 1973-04-25
US3809714A (en) * 1972-08-31 1974-05-07 Interx Research Corp Novel ester of ((methylamino)methyl) benzyl alcohol
US3839584A (en) 1972-08-31 1974-10-01 Interx Research Corp Pharmaceutical compositions containing a novel ester of ((methylamino)methyl)benzyl alcohol and methods of using same
US3868461A (en) 1972-11-22 1975-02-25 Interx Research Corp Ester of 3,4-dihydroxy-alpha (isopropylamino) methyl benzyl alcohol, composition and anti-asthma use thereof
US4035405A (en) 1976-07-09 1977-07-12 Interx Research Corporation Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives
US4180586A (en) 1977-01-10 1979-12-25 Interx Research Corporation 3,4-Dipivalyl-α-[methylamino)methyl]benzyl alcohol as an adjunct in the treatment of circulatory shock
US4094983A (en) 1977-01-17 1978-06-13 Interx Research Corporation Method for reducing intraocular pressure in warm-blooded animals
US4145441A (en) 1977-11-04 1979-03-20 Interx Research Corporation Sympathomimetic amines exhibiting anti-hemorrhoidal activity
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
CA2125579C (en) 1991-12-17 2005-06-21 Richard C. Fuisz Ulcer prevention treatment composition and method
US5654003A (en) 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5925682A (en) 1995-11-20 1999-07-20 Immunotech Inc. Epinephrine as inhibitor of cancerous tumors
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
BR0211317A (pt) * 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
JPWO2003041740A1 (ja) * 2001-11-16 2005-03-03 味の素株式会社 腫瘍壊死剤
JP2004231557A (ja) * 2003-01-30 2004-08-19 Katsuyoshi Hori エピネフリン含有抗腫瘍剤
WO2004096193A1 (en) 2003-05-02 2004-11-11 Warner-Lambert Company Llc Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
JP2006193440A (ja) * 2005-01-12 2006-07-27 Medorekkusu:Kk β２刺激剤含有製剤
WO2007028247A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
WO2013059629A1 (en) 2011-10-21 2013-04-25 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20150164827A1 (en) * 2005-09-09 2015-06-18 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20070202163A1 (en) * 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
US20070293582A1 (en) 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
KR101577471B1 (ko) * 2007-11-16 2015-12-14 알러간, 인코포레이티드 자색반병의 치료를 위한 조성물 및 방법
DE102008007198A1 (de) * 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
US20120322884A1 (en) * 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2015034822A1 (en) 2013-09-03 2015-03-12 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
GB201419257D0 (en) * 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
WO2017066787A1 (en) 2015-10-17 2017-04-20 Lebedyeva Iryna O Compounds, compositions, and methods of making and using the same
CN106109459A (zh) * 2016-06-22 2016-11-16 丁俣汀 盐酸地匹福林的药物组合物及其在生物医药中的应用
CN110418639B (zh) 2016-11-13 2023-06-02 艾奥诺医药有限公司 肾上腺素前药的舌下或口含给药制剂
DK3678648T3 (da) 2017-09-08 2023-09-11 Insignis Therapeutics Inc Fremgangsmåder til anvendelse af dipivefrin
EP3930685A1 (en) 2019-03-01 2022-01-05 Insignis Therapeutics, Inc. Dipivefrin orally disintegrating tablet formulations

Also Published As

Publication number Publication date
US20220193010A1 (en) 2022-06-23
EP3678648A1 (en) 2020-07-15
CN111565716A (zh) 2020-08-21
US11213496B2 (en) 2022-01-04
IL272851A (en) 2020-04-30
KR102182559B1 (ko) 2020-11-24
JP2020528928A (ja) 2020-10-01
US20190076378A1 (en) 2019-03-14
CA3075271C (en) 2021-10-12
WO2019051387A1 (en) 2019-03-14
KR20200040898A (ko) 2020-04-20
BR112020004586A2 (pt) 2020-09-08
EP3678648B1 (en) 2023-07-26
AU2018330329B2 (en) 2020-12-03
IL272851B (en) 2021-12-01
AU2018330329A1 (en) 2020-03-12
SG11202001397VA (en) 2020-03-30
CN111565716B (zh) 2023-06-09
CA3075271A1 (en) 2019-03-14
JP2021063135A (ja) 2021-04-22
DK3678648T3 (da) 2023-09-11
JP6837700B2 (ja) 2021-03-03
ES2954361T3 (es) 2023-11-21

Similar Documents

Publication Publication Date Title
EA202090637A1 (ru) Способы применения дипивефрина
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
TN2013000414A1 (en) 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2015005798A (es) Terapia de combinacion.
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
MX2019003039A (es) Forma de dosificacion de alivio prolongado.
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer